ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC lowered its position in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) by 15.9% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 123,420 shares of the company’s stock after selling 23,257 shares during the quarter. Los Angeles Capital Management LLC owned 0.25% of ALX Oncology worth $1,838,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in ALX Oncology during the fourth quarter worth about $28,000. China Universal Asset Management Co. Ltd. raised its stake in shares of ALX Oncology by 445.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,762 shares of the company’s stock worth $86,000 after buying an additional 4,706 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of ALX Oncology in the 3rd quarter valued at approximately $48,000. Forefront Analytics LLC purchased a new stake in shares of ALX Oncology in the third quarter valued at approximately $66,000. Finally, J.P. Morgan Private Wealth Advisors LLC acquired a new position in ALX Oncology during the third quarter worth $96,000. Institutional investors and hedge funds own 97.97% of the company’s stock.

Insider Buying and Selling

In related news, insider Jaume Pons sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $14.20, for a total transaction of $710,000.00. Following the completion of the transaction, the insider now owns 604,205 shares of the company’s stock, valued at $8,579,711. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Jaume Pons sold 50,000 shares of ALX Oncology stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $14.20, for a total value of $710,000.00. Following the transaction, the insider now owns 604,205 shares in the company, valued at $8,579,711. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jason Lettmann purchased 4,400 shares of the stock in a transaction on Thursday, March 14th. The shares were purchased at an average cost of $11.31 per share, with a total value of $49,764.00. Following the transaction, the chief executive officer now owns 171,620 shares of the company’s stock, valued at approximately $1,941,022.20. The disclosure for this purchase can be found here. Corporate insiders own 50.30% of the company’s stock.

ALX Oncology Price Performance

ALXO stock opened at $17.56 on Wednesday. The stock has a market capitalization of $878.00 million, a price-to-earnings ratio of -4.68 and a beta of 1.30. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.05. ALX Oncology Holdings Inc. has a 52-week low of $3.94 and a 52-week high of $17.83. The stock’s fifty day simple moving average is $13.67 and its 200-day simple moving average is $12.65.

ALX Oncology (NASDAQ:ALXO) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.09). Equities research analysts expect that ALX Oncology Holdings Inc. will post -3.33 EPS for the current year.

Analyst Upgrades and Downgrades

ALXO has been the subject of a number of recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a report on Friday, April 12th. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of ALX Oncology in a research report on Wednesday, April 10th. Finally, Stifel Nicolaus restated a “hold” rating and issued a $14.00 price target (up previously from $10.00) on shares of ALX Oncology in a research report on Friday, March 8th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $18.83.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.